Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-24 @ 9:14 PM
NCT ID:
NCT03397004
Eligibility Criteria:
Inclusion Criteria:
* Age \>+ 18 years
* Clinical HHT diagnosis or genetic diagnosis of HHT
* Known personal or familial endoglin (ENG), ALK1 or SMAD4 mutation
* Epistaxis at least 15 min per week (mean for past month)
* At least two skin telangiectases
* \>2mm diameter available for excisional biopsy,
* at least two other telangiectases (skin or mucosal) available for micro-imaging
* Ability to give written informed consent
* including compliance with the requirements of the study
Exclusion Criteria:
* Allergy/intolerance to the study drug or related agents
* Unstable medical illness
* Acute infection
* Creatinine \> upper limit of normal (ULN)
* Liver transaminases (AST or ALT) \>= 2x ULN
* Recent (within 2 month) use of study drug or other tetracycline agents
* Women who are pregnant
* Breastfeeding
* Plan to become pregnant during of the study
* Beta human chorionic gonadotropin (BHCG) level \<6 IUL (re-test if 6-24 IU/L)
* Specific contra-indications for study drug
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03397004
Study Brief:
Protocol Section:
NCT03397004